Insider trading activities (stock purchases, sales, and option exercises)
reported by insiders of Rubius Therapeutics, Inc. (RUBY)
since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Rubius Therapeutics, Inc. since year 2005.
Table 2 shows the detailed insider transactions of Rubius Therapeutics, Inc. since 2005.
The reporting company's ticker symbol is RUBY. The reporting company's CIK number is 1709401.
The total value of stock buying since 2005 is $864,800.
The total value of stock sales since 2005 is $1,295,292.
The total value of stock option exercises since 2005 is $240,009.
|Trading Period||Insider Buying||Insider Sales||Option Exercises|
|Trade Date||Insider Name||Trade Type||Shares||Price ($)||Value ($)|
|2019-04-15||Langer Robert (Director)||Sale||7,500||17.57||131,797|
|2019-04-15||Langer Robert (Director)||Option Ex||7,500||.15||1,125|
|2019-04-08||Nissen Torben Straight (President)||Sale||2,100||20.00||42,000|
|2019-04-05||Nissen Torben Straight (President)||Sale||12,096||20.00||241,920|
|2019-04-03||Nissen Torben Straight (President)||Sale||500||20.00||10,000|
|2019-03-15||Carpenter Christopher L. (Chief Medical Officer)||Sale||48,000||15.84||760,128|
|2019-03-15||Carpenter Christopher L. (Chief Medical Officer)||Option Ex||48,000||2.87||137,760|
|2019-01-22||Carpenter Christopher L. (Chief Medical Officer)||Option Ex||34,843||2.87||99,999|
|2019-01-14||Langer Robert (Director)||Sale||7,500||14.59||109,447|
|2019-01-14||Langer Robert (Director)||Option Ex||7,500||.15||1,125|
|2018-07-20||Symonds Jonathan (Director)||Buy||25,000||23.00||575,000|
|2018-07-20||Pomerantz Roger (Director)||Buy||100||23.00||2,300|
|2018-07-20||Sohn Catherine A. (Director)||Buy||2,500||23.00||57,500|
|2018-07-20||Cuss Francis M (Director)||Buy||10,000||23.00||230,000|
Insider trading activities including stock purchases, stock sales, and option exercises of RUBY listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Rubius Therapeutics, Inc. (symbol RUBY, CIK number 1709401) see the Securities and Exchange Commission (SEC) website.